Inhaled Corticosteroids in COPD: Trying to Make a Long Story Short

References

• Global Initiative for Chronic Obstructive Lung Disease. Progetto Mondiale BPCO Strategia Globale Per La Diagnosi, Il Trattamento E La Prevenzione Della Broncopneumopatia Cronica Ostruttiva; Aggiornamento 2016 [World COPD Project Global Strategy For Diagnosis, Treatment And Prevention Of Chronic Obstructive Pulmonary Disease; Update 2016]. Available from: http://goldcopd.it/wp-content/uploads/materiali/2016/GOLD_workshop_report_2016.pdf. Accessed 53, 2017 Italian.
   Google Scholar
• VestboJ, SorensenT, LangeP, BrixA, TorreP, ViskumK. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomized controlled trial. Lancet. 1999;353:1819–1823. doi:10.1016/S0140-6736(98)10019-310359405
   PubMed Web of Science ®Google Scholar
• PauwelsRA, LofdhalGG, LaitinenLA, et al. Long term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society study on chronic obstructive pulmonary disease. N Engl J Med. 1999;340:1948–1953. doi:10.1056/NEJM19990624340250310379018
   PubMed Web of Science ®Google Scholar
• The Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med. 2000;343:1902–1909. doi:10.1056/NEJM20001228343260111136260
   PubMed Web of Science ®Google Scholar
• CarlverleyPMA, PauwelsRA, VestboJ, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomized controlled trial. Lancet. 2003;361:449–453. doi:10.1016/S0140-6736(03)12459-212583942
   PubMed Web of Science ®Google Scholar
• CalverleyPMA, AndersonJA, CelliB, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775–789. doi:10.1056/NEJMoa06307017314337
   PubMed Web of Science ®Google Scholar
• KardosP, WenkerM, GlaabT, VolgelmeierC. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbation in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175:144–149. doi:10.1164/rccm.200602-244OC17053207
   PubMed Web of Science ®Google Scholar
• WedzichaJA, CalverleyPMA, SeemungalTA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med. 2008;177:19–26. doi:10.1164/rccm.200707-973OC17916806
   PubMed Web of Science ®Google Scholar
• TantucciC, PiniL. COPD it is time to change! Int J Chron Obstruct Pulmon Dis. 2015;10:2451–2457. doi:10.2147/COPD.S8769626648707
   PubMed Web of Science ®Google Scholar
• BrusselleG, PriceD, Gruffydd-JonesK, et al. The inevitable drift to triple therapy in COPD: an analysis of prescribing pattern in the UK. Int J Chron Obstruct Pulmon Dis. 2015;10:2207–2217. doi:10.2147/COPD.S9169426527869
   PubMed Web of Science ®Google Scholar
• JenR, RennardSI, SinDD. Effects of inhaled corticosteroids on airway inflammation in chronic obstructive pulmonary disease: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2012;7:587–595. doi:10.2147/COPD.S3276523055709
   PubMed Web of Science ®Google Scholar
• HoggJC, ChuFS, UtokaparchS, et al. The nature of small airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004;350:2645–2653. doi:10.1056/NEJMoa03215815215480
   PubMed Web of Science ®Google Scholar
• GanWQ, ManSF, SinDD. Effects of inhaled corticosteroids on sputum cell counts in stable chronic obstructive pulmonary disease: a systematic review and a meta-analysis. BMC Pulm Med. 2005;5:3. doi:10.1186/1471-2466-5-315707484
   PubMedGoogle Scholar
• BalzanoG, StefanelliF, IorioC, et al. Eosinophilic inflammation in stable chronic obstructive pulmonary disease. Relationship with neutrophils and airway function. Am J Respir Crit Care Med. 1999;160:1486–1492. doi:10.1164/ajrccm.160.5.981010510556110
   PubMed Web of Science ®Google Scholar
• PerngDW, HuangHY, ChenHM, LeeYC, PerngRP. Characteristic of airway inflammation and bronchodilator reversibility in COPD: a potential guide to treatment. Chest. 2004;126:375–381. doi:10.1378/chest.126.2.37515302720
   PubMed Web of Science ®Google Scholar
• BrightilngCE, McKennaS, HargadonB, et al. Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax. 2005;60:193–198. doi:10.1136/thx.2004.03251615741434
   PubMed Web of Science ®Google Scholar
• DummerJF, EptonMJ, CowanJO, et al. Predicting corticosteroids response in chronic obstructive pulmonary disease using exhaled nitic oxide. Am J Respir Crit Care Med. 2009;180:846–852. doi:10.1164/rccm.200905-0685OC19661244
   PubMed Web of Science ®Google Scholar
• HoonhorstSJM, Ten HackenNHT, VonkJM, et al. Steroid resistance in COPD? Overlap and differential anti-inflammatory effects in smokers and ex-smokers. PLoS One. 2014;9(2):e87443. doi:10.1371/journal.pone.008744324505290
   PubMed Web of Science ®Google Scholar
• BarnesPJ, AdcockIM, ItoK. Histone acetylation and deacetylation: importance in inflammatory lung diseases. Eur Respir J. 2005;25:552–563. doi:10.1183/09031936.05.0011750415738302
   PubMed Web of Science ®Google Scholar
• KunzLIZ, StrebusJ, BudulacSE, et al. Inhaled steroids modulate extracellular matrix composition in bronchial biopsies of COPD patients: a randomized, controlled trial. PLoS One. 2013;8(5):e63430. doi:10.1371/journal.pone.006343023667615
   PubMed Web of Science ®Google Scholar
• GlaabT, TaubeC. Effects of inhaled corticosteroids in stable chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2011;24:15–22. doi:10.1016/j.pupt.2010.08.00620816832
   PubMed Web of Science ®Google Scholar
• LynchDA, AustinJH, HoggJC, et al. CT-definable subtypes of chronic obstructive pulmonary disease: a statement of Fleischner Society. Radiology. 2015;277:192–205. doi:10.1148/radiol.201514157925961632
   PubMed Web of Science ®Google Scholar
• BhattSP, SolerX, WangS, et al. Association between functional small airway disease and FEV1 decline in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2016;194:178–184. doi:10.1164/rccm.201511-2219OC26808615
   PubMed Web of Science ®Google Scholar
• ZhangX, MoilanenE, KankaanrantaH. Beclomethasone, budesonide and fluticasone propionate inhibit human neutrophil apoptosis. Eur J Pharmacol. 2001;431:365–371.11730731
   PubMed Web of Science ®Google Scholar
• LapperreTS, Snoeck-StrobandJB, GosmanMME, et al. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease. Ann Intern Med. 2009;151:517–527. doi:10.7326/0003-4819-151-8-200910200-0000419841453
   PubMed Web of Science ®Google Scholar
• Snoeck-StrobandJB, LaperreTS, SterkPJ, et al. Prediction of long-term benefits of inhaled steroids by phenotypic markers in moderate-to-severe COPD: a randomized controlled trial. PLoS One. 2015;10(12):e0143793. doi:10.1371/journal.pone.014379326659582
   PubMed Web of Science ®Google Scholar
• NishimuraM, MakitaH, NagaiK, et al. Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;185:44–52. doi:10.1164/rccm.201106-0992OC22016444
   PubMed Web of Science ®Google Scholar
• PizzichiniE, PizzichiniMMM, GibsonP, et al. Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis. Am J Respir Crit Care Med. 1998;158:1511–1517. doi:10.1164/ajrccm.158.5.98040289817701
   PubMed Web of Science ®Google Scholar
• LeighR, PizzichiniMMM, MorrisMM, MaltaisF, HargreaveFE, PizzichiniE. Stabel COPD: predicting benefit from high-dose of inhaled corticosteroid treatment. Eur Respir J. 2006;27:964–971. doi:10.1183/09031936.06.0007210516446316
   PubMed Web of Science ®Google Scholar
• SteilingK, van den BergeM, HijaziK, et al. A dynamic bronchial airway gene expression signature of chronic obstructive pulmonary disease and lung function impairment. Am J Respir Crit Care Med. 2013;187:933–942. doi:10.1164/rccm.201208-1449OC23471465
   PubMed Web of Science ®Google Scholar
• van den BergeM, SteilingK, TimensW, et al. Airway gene expression in COPD is dynamic with inhaled corticosteroid treatment and reflects biological pathways associated with disease activity. Thorax. 2014;69:14–23. doi:10.1136/thoraxjnl-2012-20287823925644
   PubMed Web of Science ®Google Scholar
• ChristensonSA, SteilingK, van den BergeM, et al. Asthma-COPD overlap. Clinical relevance of genomic signatures of type-2 inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;191.
   Web of Science ®Google Scholar
• BafadhelM, McKennaS, TerryS, et al. Acute exacerbations of chronic obstructive pulmonary disease. Identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med. 2011;184:662–671. doi:10.1164/rccm.201104-0597OC21680942
   PubMed Web of Science ®Google Scholar
• BafadhelM, McKennaS, TerryS, et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186:48–55. doi:10.1164/rccm.201108-1553OC22447964
   PubMed Web of Science ®Google Scholar
• PascoeS, LocantoreN, DransfieldMT, BarnesNC, PavordID. Blood eosinophil count, exacerbations and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomized controlled trials. Lancet Resp Med. 2015;435–442. doi:10.1016/S2213-2600(15)00106-X
   PubMed Web of Science ®Google Scholar
• SiddiquiSH, GuasconiA, VestboJ, et al. Blood eosinophils: a biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;192:523–526. doi:10.1164/rccm.201502-0235LE26051430
   PubMed Web of Science ®Google Scholar
• WedzichaJA, PriceD, Karen MezziK, FogelR, BanerjiD. Indacaterol plus Glypirronium compared with salmeterol/fluticasone on exacerbations and its correlation with baseline blood eosinophils: a pooled analysis of Lantern and Illuminate. Eur Respir J. 2015;46.
   Google Scholar
• FergusonGT, RabeKF, MartinezFJ, et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, Phase 3 randomised controlled trial. Lancet Resp Med. 2018;6:747–758.
   PubMed Web of Science ®Google Scholar
• WatzH, TetzlaffK, WoutersEF, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled c orticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Resp Med. 2016;4:390–398. doi:10.1016/S2213-2600(16)00100-4
   PubMed Web of Science ®Google Scholar
• BafadhelM, PetersonS, De BlasMA, et al. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respir Med. 2018;6:117–126. doi:10.1016/S2213-2600(18)30006-729331313
   PubMed Web of Science ®Google Scholar
• LipsonDA, BarnhartF, BrealeyN, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. New Engl J Med. 2018;378:1671–1680. doi:10.1056/NEJMoa171390129668352
   PubMed Web of Science ®Google Scholar
• SuissaS, Dell’AnielloS, ErnstP. Comparative effectiveness of LABA-ICS versus LAMA as initial treatment in COPD targeted by blood eosinophils: a population-based cohort study. Lancet Resp Med. 2018;6:855–862. doi:10.1016/S2213-2600(18)30368-0
   PubMed Web of Science ®Google Scholar
• BrusselleGG, BrackeK, LahousseL. Targeted therapy with inhaled corticosteroids in COPD according to blood eosinophil counts. Lancet Resp Med. 2015;3:416–417. doi:10.1016/S2213-2600(15)00145-9
   PubMed Web of Science ®Google Scholar
• NegewoNA, McDonaldVM, BainesKJ, et al. Peripheral blood eosinophils: a surrogate marker for airway eosinophilia in stable COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:1495.27445469
   PubMed Web of Science ®Google Scholar
• BarnesNC, SharmaR, LettisS, CalverleyPMA. Blood eosinophils as a marker of response to inhaled corticosteroids in COPD. Eur Respir J. 2016;47:1374–1382. doi:10.1183/13993003.01370-201526917606
   PubMed Web of Science ®Google Scholar
• AlbertP, AgustiA, EdwardsL, et al. Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease. Thorax. 2012;67:701–708. doi:10.1136/thoraxjnl-2011-20145822696176
   PubMed Web of Science ®Google Scholar
• PapiA, RomagnoliM, BaraldoS, et al. Partial reversibility of airflow limitation and increased exhaled NO and sputum eosinophilia in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;162:1773–1777. doi:10.1164/ajrccm.162.5.991011211069811
   PubMed Web of Science ®Google Scholar
• SitkauskieneB, SakalaukasR, MalakauskasK, LotvallJ. Reversibility to a beta-2-agonist in COPD: relationship to atopy and neutrophil activation. Resp Med. 2003;97:591–598. doi:10.1053/rmed.2003.1485
   PubMed Web of Science ®Google Scholar
• ErnstP, SaadN, SuissaS. Inhaled corticosteroids in COPD: the clinical evidence. Eur Respir J. 2015;45:525–537. doi:10.1183/09031936.0012891425537556
   PubMed Web of Science ®Google Scholar
• CerveriI, PellegrinoR, DoreR, et al. Mechanisms for isolated volume response to bronchodilator in patients with COPD. J Appl Physiol. 2000;88:1989–1995. doi:10.1152/jappl.2000.88.6.198910846010
   PubMed Web of Science ®Google Scholar
• HurstJR, VestboJ, AnzuetoA, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363:1128–1138. doi:10.1056/NEJMoa090988320843247
   PubMed Web of Science ®Google Scholar
• Soler-CatalunaJJ, Martìnez-GarcìaMA, Romàn SanchezP, SalcedoE, NavarroM, OchandoR. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005;60:925–931. doi:10.1136/thx.2005.04052716055622
   PubMed Web of Science ®Google Scholar
• PavordID, JonesPW, BurgelP-R, RabeKF. Exacerbation of COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:21–30. doi:10.2147/COPD.S8597826937187
   PubMed Web of Science ®Google Scholar
• WedzichaJA, MiravittlesM, HurstJR, et al. Management of COPD exacerbation: a European Respiratory Society/american Thoracic Society guideline. Eur Respir J. 2017;49:1600791. doi:10.1183/13993003.00791-201628298398
   PubMed Web of Science ®Google Scholar
• ZhouA, ZhouZ, ZhaoY, ChenP. The recent advances of phenotypes in acute exacerbations of COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:1009–1018. doi:10.2147/COPD.S12860428392685
   PubMed Web of Science ®Google Scholar
• HurstJR. Exacerbation phenotyping in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2011;184:625–626. doi:10.1164/rccm.201106-1136ED21920921
   PubMed Web of Science ®Google Scholar
• SuissaS, PatenaudeV, LapiF, et al. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax. 2013;68:1029–1036. doi:10.1136/thoraxjnl-2012-20287224130228
   PubMed Web of Science ®Google Scholar
• SuissaS, ErnstP. Precision medicine urgency: the case of inhaled corticosteroids in COPD. Chest. 2017;152:227–231. doi:10.1016/j.chest.2017.05.02028797382
   PubMed Web of Science ®Google Scholar
• SantosS, MarinA, Serra-BatllesJ, et al. Treatment of patients with COPD and recurrent exacerbations: the role of infection and inflammation. Int J Chron Obstruct Pulmon Dis. 2016;11:515–525. doi:10.2147/COPD.S9833327042040
   PubMed Web of Science ®Google Scholar
• Global Initiative for asthma (GINA). Global strategy for asthma management and prevention; 2018 Available from: http://www.ginasthma.org/guideline-report-2018.htlm. Accessed 326, 2020.
   Google Scholar
• GibsonPG, SimpsonJL. The overlap syndrome of asthma and COPD: what are its feature and how important is it? Thorax. 2009;64:728–735. doi:10.1136/thx.2008.10802719638566
   PubMed Web of Science ®Google Scholar
• KitaguchiYK, KomatsuY, FujimotoK, HanaokaM, KuboK. Sputum eosinophilia can predict responsiveness to inhaled corticosteroid treatment in patients with overlap syndrome of COPD and asthma. Int J Chron Obstruct Pulmon Dis. 2012;7:283–289. doi:10.2147/COPD.S3065122589579
   PubMed Web of Science ®Google Scholar
• GershonAS, CampitelliMA, CroxfordR, et al. Combination of long-acting β-agonists and inhaled corticosteroids compared with long-acting β-agonists alone in older adults with chronic obstructive pulmonary disease. JAMA. 2014;312:1114–1121. doi:10.1001/jama.2014.1143225226477
   PubMed Web of Science ®Google Scholar
• AlmirallJ, BolibarI, Serra-PrtaM, et al. New evidence of risk factors for community-acquired pneumonia: a population-based study. Eur Respir J. 2008;31:1274–1284. doi:10.1183/09031936.0009580718216057
   PubMed Web of Science ®Google Scholar
• CrimC, CalvereleyPM, AndersonJA, et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J. 2009;34:641–647. doi:10.1183/09031936.0019390819443528
   PubMed Web of Science ®Google Scholar
• KewKM, SeniukovichA. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Sys Rev. 2014;CD010115.
   PubMed Web of Science ®Google Scholar
• FergusonGT, AnzuetoA, FeiR, EmmetA, KnobilK, KalbergC. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations. Respir Med. 2008;102:1099–1108. doi:10.1016/j.rmed.2008.04.01918614347
   PubMed Web of Science ®Google Scholar
• AnzuetoA, FergusonGT, FeldmanG, et al. Effect of fluticasone propionate/salmeterol (250/50 microg) on COPD exacerbations and impact on patient outcomes. COPD. 2009;6:320–329. doi:10.1080/1541255090314088119863361
   PubMedGoogle Scholar
• VestboJ, PapiA, CorradiM, et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind parallel group, randomized controlled trial. Lancet. 2017;389:1919–1929. doi:10.1016/S0140-6736(17)30188-528385353
   PubMed Web of Science ®Google Scholar
• PapiA, VestboJ, FabbriL, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind parallel group, randomized controlled trial. Lancet. 2018;391:1076–1084. doi:10.1016/S0140-6736(18)30206-X29429593
   PubMed Web of Science ®Google Scholar